Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Axel Heidenreich, Silke Gillessen, Daniel Heinrich, Daniel Keizman, Joe M. O’Sullivan, Joan Carles, Manfred Wirth, Kurt Miller, John Reeves, Monica Seger, Sten Nilsson, Fred Saad

ABSTRACT

BACKGROUND: Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking. METHODS: This was a prospective, single-arm phase 3b study. Patients with metastatic CRPC (malignant lymphadenopathy not exceeding 6 cm was allowed, visceral disease was excluded) received radium-223, 55 kBq/kg intravenously, every 4 weeks for up to 6 cycles. Co-primary endpoints were safety and overall survival. Post hoc analyses were performed according to baseline asymptomatic or symptomatic disease status. Asymptomatic status was defined as no pain and no opioid use at baseline. RESULTS: Seven hundred eight patients received ≥1 radium-223 injection: 548 (77%) were symptomatic to various degrees, and 135 (19%) were asymptomatic. Asymptomatic patients had more favorable baseline disease characteristics than symptomatic. A lower proportion of asymptomatic versus symptomatic patients had received prior abiraterone (25% vs 35%) and prior docetaxel (52% vs 62%). A higher proportion of asymptomatic (71%) versus symptomatic (55%) patients completed radium-223 treatment. Overall survival (hazard ratio [HR] 0.486), time to disease progression (HR 0.722) and time to first symptomatic skeletal event (HR 0.328) were better in asymptomatic than symptomatic patients. Alkaline phosphatase (ALP) response rates were similar (46% vs 47%), and ALP normalization (44% vs 25%) and prostate-specific antigen response rates (21% vs 13%) were higher in asymptomatic than symptomatic patients. A lower proportion of asymptomatic patients reported treatment-emergent adverse events (TEAEs, 61% vs 79%), grade 3-4 TEAEs (29% vs 40%) and drug-related TEAEs (28% vs 44%). There were two treatment-related deaths, both in patients with baseline symptomatic disease. CONCLUSIONS: Using radium-223 earlier in the disease course, when patients are asymptomatic or minimally symptomatic, may enable patients to complete treatment and optimize treatment outcome compared to symptomatic patients, and therefore may allow sequencing with other life-prolonging therapies. TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov , number NCT01618370 on June 13, 2012 and the European Union Clinical Trials Register, EudraCT number 2012-000075-16 on April 4, 2012. More... »

PAGES

12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-018-5203-y

DOI

http://dx.doi.org/10.1186/s12885-018-5203-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111201179

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30612558


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital Cologne", 
          "id": "https://www.grid.ac/institutes/grid.411097.a", 
          "name": [
            "Department of Urology, University Hospital Cologne, Cologne, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heidenreich", 
        "givenName": "Axel", 
        "id": "sg:person.0735602015.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735602015.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Bern", 
          "id": "https://www.grid.ac/institutes/grid.5734.5", 
          "name": [
            "Division of Cancer Sciences, University of Manchester and the Christie, Manchester, UK", 
            "Medical Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland", 
            "University of Bern, Bern, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gillessen", 
        "givenName": "Silke", 
        "id": "sg:person.0725505426.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725505426.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Akershus University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411279.8", 
          "name": [
            "Department of Oncology, Akershus University Hospital, L\u00f8renskog, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heinrich", 
        "givenName": "Daniel", 
        "id": "sg:person.0577622242.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577622242.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meir Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.415250.7", 
          "name": [
            "Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Kfar-Saba, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Keizman", 
        "givenName": "Daniel", 
        "id": "sg:person.0721414343.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721414343.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Clinical Oncology, The Centre for Cancer Research and Cell Biology, Queen\u2019s University Belfast and the Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Sullivan", 
        "givenName": "Joe M.", 
        "id": "sg:person.01330530232.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330530232.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitari Vall d'Hebron", 
          "id": "https://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Department of Medical Oncology, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carles", 
        "givenName": "Joan", 
        "id": "sg:person.0633222263.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633222263.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Carl Gustav Carus", 
          "id": "https://www.grid.ac/institutes/grid.412282.f", 
          "name": [
            "Department of Urology, University Hospital Carl-Gustav Carus, Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wirth", 
        "givenName": "Manfred", 
        "id": "sg:person.01324022365.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324022365.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Department of Urology, Charit\u00e9 University Medicine Berlin, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Kurt", 
        "id": "sg:person.0636004620.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636004620.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pharmaceutical Division of Bayer, Whippany, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reeves", 
        "givenName": "John", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pharmaceutical Division of Bayer, Whippany, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seger", 
        "givenName": "Monica", 
        "id": "sg:person.015656226641.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015656226641.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Karolinska University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Department of Oncology, Karolinska University Hospital, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nilsson", 
        "givenName": "Sten", 
        "id": "sg:person.013640713242.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013640713242.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al", 
          "id": "https://www.grid.ac/institutes/grid.410559.c", 
          "name": [
            "Department of Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saad", 
        "givenName": "Fred", 
        "id": "sg:person.01123410561.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123410561.52"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2007.12.4008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004102684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71205-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013268426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1405095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017836241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-0841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017867696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1014618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018044872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70183-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028190847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv222", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034730241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(16)31349-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035496738"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv594", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036694080"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.52.3696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040296195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1207506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044642614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30173-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045008147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2016.06.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046083169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1213755", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046224838"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw065", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051601206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075060924", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-16-2955", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084230890"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085373933"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2017.06.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086157627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clgc.2017.09.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092167399"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.5082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106842039"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking.\nMETHODS: This was a prospective, single-arm phase 3b study. Patients with metastatic CRPC (malignant lymphadenopathy not exceeding 6\u2009cm was allowed, visceral disease was excluded) received radium-223, 55\u2009kBq/kg intravenously, every 4\u2009weeks for up to 6\u2009cycles. Co-primary endpoints were safety and overall survival. Post hoc analyses were performed according to baseline asymptomatic or symptomatic disease status. Asymptomatic status was defined as no pain and no opioid use at baseline.\nRESULTS: Seven hundred eight patients received \u22651 radium-223 injection: 548 (77%) were symptomatic to various degrees, and 135 (19%) were asymptomatic. Asymptomatic patients had more favorable baseline disease characteristics than symptomatic. A lower proportion of asymptomatic versus symptomatic patients had received prior abiraterone (25% vs 35%) and prior docetaxel (52% vs 62%). A higher proportion of asymptomatic (71%) versus symptomatic (55%) patients completed radium-223 treatment. Overall survival (hazard ratio [HR] 0.486), time to disease progression (HR 0.722) and time to first symptomatic skeletal event (HR 0.328) were better in asymptomatic than symptomatic patients. Alkaline phosphatase (ALP) response rates were similar (46% vs 47%), and ALP normalization (44% vs 25%) and prostate-specific antigen response rates (21% vs 13%) were higher in asymptomatic than symptomatic patients. A lower proportion of asymptomatic patients reported treatment-emergent adverse events (TEAEs, 61% vs 79%), grade 3-4 TEAEs (29% vs 40%) and drug-related TEAEs (28% vs 44%). There were two treatment-related deaths, both in patients with baseline symptomatic disease.\nCONCLUSIONS: Using radium-223 earlier in the disease course, when patients are asymptomatic or minimally symptomatic, may enable patients to complete treatment and optimize treatment outcome compared to symptomatic patients, and therefore may allow sequencing with other life-prolonging therapies.\nTRIAL REGISTRATION: The study was registered with ClinicalTrials.gov , number NCT01618370 on June 13, 2012 and the European Union Clinical Trials Register, EudraCT number 2012-000075-16 on April 4, 2012.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-018-5203-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program", 
    "pagination": "12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "62ef0745b7774dcf6c4297fcbeaefbc6a2a7c7fc68e395c3e70462c122ef28c7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30612558"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-018-5203-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111201179"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-018-5203-y", 
      "https://app.dimensions.ai/details/publication/pub.1111201179"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000315_0000000315/records_6336_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-018-5203-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5203-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5203-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5203-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5203-y'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      21 PREDICATES      50 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-018-5203-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ndf9ce5667ace4b72930e7dddd21f6f17
4 schema:citation https://app.dimensions.ai/details/publication/pub.1075060924
5 https://doi.org/10.1016/j.clgc.2017.09.015
6 https://doi.org/10.1016/j.eururo.2016.06.002
7 https://doi.org/10.1016/j.eururo.2017.06.002
8 https://doi.org/10.1016/s0959-8049(16)31349-1
9 https://doi.org/10.1016/s1470-2045(14)70183-4
10 https://doi.org/10.1016/s1470-2045(14)71205-7
11 https://doi.org/10.1016/s1470-2045(16)30173-5
12 https://doi.org/10.1056/nejmoa1014618
13 https://doi.org/10.1056/nejmoa1207506
14 https://doi.org/10.1056/nejmoa1213755
15 https://doi.org/10.1056/nejmoa1405095
16 https://doi.org/10.1093/annonc/mdv222
17 https://doi.org/10.1093/annonc/mdv594
18 https://doi.org/10.1093/annonc/mdw065
19 https://doi.org/10.1093/annonc/mdx044
20 https://doi.org/10.1158/1078-0432.ccr-06-0841
21 https://doi.org/10.1158/1078-0432.ccr-16-2955
22 https://doi.org/10.1200/jco.2007.12.4008
23 https://doi.org/10.1200/jco.2013.52.3696
24 https://doi.org/10.1200/jco.2016.34.15_suppl.5082
25 schema:datePublished 2019-12
26 schema:datePublishedReg 2019-12-01
27 schema:description BACKGROUND: Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking. METHODS: This was a prospective, single-arm phase 3b study. Patients with metastatic CRPC (malignant lymphadenopathy not exceeding 6 cm was allowed, visceral disease was excluded) received radium-223, 55 kBq/kg intravenously, every 4 weeks for up to 6 cycles. Co-primary endpoints were safety and overall survival. Post hoc analyses were performed according to baseline asymptomatic or symptomatic disease status. Asymptomatic status was defined as no pain and no opioid use at baseline. RESULTS: Seven hundred eight patients received ≥1 radium-223 injection: 548 (77%) were symptomatic to various degrees, and 135 (19%) were asymptomatic. Asymptomatic patients had more favorable baseline disease characteristics than symptomatic. A lower proportion of asymptomatic versus symptomatic patients had received prior abiraterone (25% vs 35%) and prior docetaxel (52% vs 62%). A higher proportion of asymptomatic (71%) versus symptomatic (55%) patients completed radium-223 treatment. Overall survival (hazard ratio [HR] 0.486), time to disease progression (HR 0.722) and time to first symptomatic skeletal event (HR 0.328) were better in asymptomatic than symptomatic patients. Alkaline phosphatase (ALP) response rates were similar (46% vs 47%), and ALP normalization (44% vs 25%) and prostate-specific antigen response rates (21% vs 13%) were higher in asymptomatic than symptomatic patients. A lower proportion of asymptomatic patients reported treatment-emergent adverse events (TEAEs, 61% vs 79%), grade 3-4 TEAEs (29% vs 40%) and drug-related TEAEs (28% vs 44%). There were two treatment-related deaths, both in patients with baseline symptomatic disease. CONCLUSIONS: Using radium-223 earlier in the disease course, when patients are asymptomatic or minimally symptomatic, may enable patients to complete treatment and optimize treatment outcome compared to symptomatic patients, and therefore may allow sequencing with other life-prolonging therapies. TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov , number NCT01618370 on June 13, 2012 and the European Union Clinical Trials Register, EudraCT number 2012-000075-16 on April 4, 2012.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N5fdcb6903ddf4034b0a8b97d8af4ffbd
32 N6cdfa46f6b1445b49ae68b4070b7c138
33 sg:journal.1024632
34 schema:name Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
35 schema:pagination 12
36 schema:productId N4fa28b094c7b4dd8a6296c0eb1878314
37 N4fbc7d0d8031479ca0c7e8d1e090242e
38 N9ed1d8e7413644c78acff856d5b87011
39 Nb82d92e84a1e41ceb84b253f8188c3e9
40 Ndce61bc564ce4fb5848c69fc252a9a63
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111201179
42 https://doi.org/10.1186/s12885-018-5203-y
43 schema:sdDatePublished 2019-04-11T08:37
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher N9a0026e29be241ed91822ebad3753ad9
46 schema:url https://link.springer.com/10.1186%2Fs12885-018-5203-y
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N03d751c0d5384239bb9a5836d062db7c schema:name Pharmaceutical Division of Bayer, Whippany, NJ, USA
51 rdf:type schema:Organization
52 N16ef11d931494a19b86b36fd7c95e016 schema:name Department of Clinical Oncology, The Centre for Cancer Research and Cell Biology, Queen’s University Belfast and the Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK
53 rdf:type schema:Organization
54 N3e097753587b472995175256e3bca239 rdf:first N970e2207495a410eb9d3c2e2f2fb1152
55 rdf:rest N6c099fd17ba54e6c879450a2ef60a8f3
56 N4d115486162e4550b682ed1de7436bd9 rdf:first sg:person.01324022365.40
57 rdf:rest Na1624f811bde48e4abfd36a13c03683b
58 N4f01527ef27a40998aa75c3475c7c44b rdf:first sg:person.0721414343.73
59 rdf:rest Nc823e22b576643d08898cc06ab892e93
60 N4fa28b094c7b4dd8a6296c0eb1878314 schema:name dimensions_id
61 schema:value pub.1111201179
62 rdf:type schema:PropertyValue
63 N4fbc7d0d8031479ca0c7e8d1e090242e schema:name doi
64 schema:value 10.1186/s12885-018-5203-y
65 rdf:type schema:PropertyValue
66 N5095a5182188404cbf18d19fe577dfbd rdf:first sg:person.01123410561.52
67 rdf:rest rdf:nil
68 N51005a44dda2480689bcb4e1635dc522 schema:name Pharmaceutical Division of Bayer, Whippany, NJ, USA
69 rdf:type schema:Organization
70 N5fdcb6903ddf4034b0a8b97d8af4ffbd schema:volumeNumber 19
71 rdf:type schema:PublicationVolume
72 N6c099fd17ba54e6c879450a2ef60a8f3 rdf:first sg:person.015656226641.29
73 rdf:rest N99618cdc2eb94b5390a2e3525defb1cd
74 N6cdfa46f6b1445b49ae68b4070b7c138 schema:issueNumber 1
75 rdf:type schema:PublicationIssue
76 N970e2207495a410eb9d3c2e2f2fb1152 schema:affiliation N03d751c0d5384239bb9a5836d062db7c
77 schema:familyName Reeves
78 schema:givenName John
79 rdf:type schema:Person
80 N9820c1e69e3b48a79ec7183010fa28ee rdf:first sg:person.0577622242.47
81 rdf:rest N4f01527ef27a40998aa75c3475c7c44b
82 N99618cdc2eb94b5390a2e3525defb1cd rdf:first sg:person.013640713242.10
83 rdf:rest N5095a5182188404cbf18d19fe577dfbd
84 N9a0026e29be241ed91822ebad3753ad9 schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 N9ed1d8e7413644c78acff856d5b87011 schema:name readcube_id
87 schema:value 62ef0745b7774dcf6c4297fcbeaefbc6a2a7c7fc68e395c3e70462c122ef28c7
88 rdf:type schema:PropertyValue
89 Na1624f811bde48e4abfd36a13c03683b rdf:first sg:person.0636004620.19
90 rdf:rest N3e097753587b472995175256e3bca239
91 Nb82d92e84a1e41ceb84b253f8188c3e9 schema:name pubmed_id
92 schema:value 30612558
93 rdf:type schema:PropertyValue
94 Nc823e22b576643d08898cc06ab892e93 rdf:first sg:person.01330530232.31
95 rdf:rest Nd3d5445f746c49b7b1e984e972ca817f
96 Nd3d5445f746c49b7b1e984e972ca817f rdf:first sg:person.0633222263.47
97 rdf:rest N4d115486162e4550b682ed1de7436bd9
98 Ndce61bc564ce4fb5848c69fc252a9a63 schema:name nlm_unique_id
99 schema:value 100967800
100 rdf:type schema:PropertyValue
101 Nde443d14f44c4bbb8670ab15ef6a8c3f rdf:first sg:person.0725505426.73
102 rdf:rest N9820c1e69e3b48a79ec7183010fa28ee
103 Ndf9ce5667ace4b72930e7dddd21f6f17 rdf:first sg:person.0735602015.61
104 rdf:rest Nde443d14f44c4bbb8670ab15ef6a8c3f
105 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
106 schema:name Medical and Health Sciences
107 rdf:type schema:DefinedTerm
108 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
109 schema:name Clinical Sciences
110 rdf:type schema:DefinedTerm
111 sg:journal.1024632 schema:issn 1471-2407
112 schema:name BMC Cancer
113 rdf:type schema:Periodical
114 sg:person.01123410561.52 schema:affiliation https://www.grid.ac/institutes/grid.410559.c
115 schema:familyName Saad
116 schema:givenName Fred
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123410561.52
118 rdf:type schema:Person
119 sg:person.01324022365.40 schema:affiliation https://www.grid.ac/institutes/grid.412282.f
120 schema:familyName Wirth
121 schema:givenName Manfred
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324022365.40
123 rdf:type schema:Person
124 sg:person.01330530232.31 schema:affiliation N16ef11d931494a19b86b36fd7c95e016
125 schema:familyName O’Sullivan
126 schema:givenName Joe M.
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330530232.31
128 rdf:type schema:Person
129 sg:person.013640713242.10 schema:affiliation https://www.grid.ac/institutes/grid.24381.3c
130 schema:familyName Nilsson
131 schema:givenName Sten
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013640713242.10
133 rdf:type schema:Person
134 sg:person.015656226641.29 schema:affiliation N51005a44dda2480689bcb4e1635dc522
135 schema:familyName Seger
136 schema:givenName Monica
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015656226641.29
138 rdf:type schema:Person
139 sg:person.0577622242.47 schema:affiliation https://www.grid.ac/institutes/grid.411279.8
140 schema:familyName Heinrich
141 schema:givenName Daniel
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577622242.47
143 rdf:type schema:Person
144 sg:person.0633222263.47 schema:affiliation https://www.grid.ac/institutes/grid.411083.f
145 schema:familyName Carles
146 schema:givenName Joan
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633222263.47
148 rdf:type schema:Person
149 sg:person.0636004620.19 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
150 schema:familyName Miller
151 schema:givenName Kurt
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636004620.19
153 rdf:type schema:Person
154 sg:person.0721414343.73 schema:affiliation https://www.grid.ac/institutes/grid.415250.7
155 schema:familyName Keizman
156 schema:givenName Daniel
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721414343.73
158 rdf:type schema:Person
159 sg:person.0725505426.73 schema:affiliation https://www.grid.ac/institutes/grid.5734.5
160 schema:familyName Gillessen
161 schema:givenName Silke
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725505426.73
163 rdf:type schema:Person
164 sg:person.0735602015.61 schema:affiliation https://www.grid.ac/institutes/grid.411097.a
165 schema:familyName Heidenreich
166 schema:givenName Axel
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735602015.61
168 rdf:type schema:Person
169 https://app.dimensions.ai/details/publication/pub.1075060924 schema:CreativeWork
170 https://doi.org/10.1016/j.clgc.2017.09.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092167399
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/j.eururo.2016.06.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046083169
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/j.eururo.2017.06.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086157627
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1016/s0959-8049(16)31349-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035496738
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1016/s1470-2045(14)70183-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028190847
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1016/s1470-2045(14)71205-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013268426
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1016/s1470-2045(16)30173-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045008147
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1056/nejmoa1014618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018044872
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1056/nejmoa1207506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044642614
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1056/nejmoa1213755 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046224838
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1056/nejmoa1405095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017836241
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1093/annonc/mdv222 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034730241
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1093/annonc/mdv594 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036694080
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1093/annonc/mdw065 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051601206
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1093/annonc/mdx044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085373933
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1158/1078-0432.ccr-06-0841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017867696
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1158/1078-0432.ccr-16-2955 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084230890
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1200/jco.2007.12.4008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004102684
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1200/jco.2013.52.3696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040296195
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1200/jco.2016.34.15_suppl.5082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106842039
209 rdf:type schema:CreativeWork
210 https://www.grid.ac/institutes/grid.24381.3c schema:alternateName Karolinska University Hospital
211 schema:name Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
212 rdf:type schema:Organization
213 https://www.grid.ac/institutes/grid.410559.c schema:alternateName Centre Hospitalier de l’Université de Montréal
214 schema:name Department of Urology, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, Canada
215 rdf:type schema:Organization
216 https://www.grid.ac/institutes/grid.411083.f schema:alternateName Hospital Universitari Vall d'Hebron
217 schema:name Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.411097.a schema:alternateName University Hospital Cologne
220 schema:name Department of Urology, University Hospital Cologne, Cologne, Germany
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.411279.8 schema:alternateName Akershus University Hospital
223 schema:name Department of Oncology, Akershus University Hospital, Lørenskog, Norway
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.412282.f schema:alternateName University Hospital Carl Gustav Carus
226 schema:name Department of Urology, University Hospital Carl-Gustav Carus, Dresden, Germany
227 rdf:type schema:Organization
228 https://www.grid.ac/institutes/grid.415250.7 schema:alternateName Meir Medical Center
229 schema:name Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Kfar-Saba, Israel
230 rdf:type schema:Organization
231 https://www.grid.ac/institutes/grid.5734.5 schema:alternateName University of Bern
232 schema:name Division of Cancer Sciences, University of Manchester and the Christie, Manchester, UK
233 Medical Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland
234 University of Bern, Bern, Switzerland
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.6363.0 schema:alternateName Charité
237 schema:name Department of Urology, Charité University Medicine Berlin, Berlin, Germany
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...